scholarly journals Exploring the influence of maternally derived antibody against hepatitis B surface antigen on infants’ immune response to hepatitis B vaccine in mice

2020 ◽  
Author(s):  
Weihong Lv ◽  
Tao Wei ◽  
Shanjuan Tan ◽  
Ling Li ◽  
Jijun Teng ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Negative Impact ◽  
Hepatitis B Surface Antigen ◽  
Multivariate Logistic Regression Analysis ◽  
Hepatitis B Vaccine ◽  
Hypodermic Injection ◽  
Response Level ◽  
Different Doses

Abstract Background: Whether maternal anti-HBs acquired transplacentally plays a negative role in newborn infants’ immune response to hepatitis B vaccine (HepB Vac), it remains controversial and has not been paid enough attention.Methods: 267 BALB/c mice were bred. All mice were divided into two groups according to different doses of HepB Vac (2μg, 5μg) injected to mice. Each group was sub-divided into three subgroups according to different doses of hepatitis B immunoglobulin (HBIG) (50 IU, 25 IU, 0 IU) injected combined with the first dose of HepB Vac. Three doses of HepB Vac were administrated at 0 week, 4week and 8 week respectively. Antibodies against hepatitis B surface antigen (anti-HBs) were tested four weeks after the third dose of HepB Vac.Results: Among 267 mice, 40 were of low- and non-response to HepB Vac (anti-HBs<100 mIU/mL). Multivariate logistic regression analysis showed that rates of anti-HBs<100 mIU/mL were: 1.1%, 23.1% and 20.7% in groups of HBIG=0 IU(1), HBIG=25 IU(2) and HBIG=50 IU(3) respectively, p = 0.002, and among subgroups, (1) vs (3), RR= 0.032, 95% CI [0.004, 0.255], p = 0.001, (2) vs (3), RR= 1.359, 95% CI [0.588, 3.144], p = 0.473; 4.5% and 25.6% in groups of HepB Vac 5μg and 2μg, RR=0.093, 95% CI [0.035, 0.250], p <0.001; 6.1% and 23.7% in groups of intramuscular injection and hypodermic injection, RR=0.139, 95% CI [0.056, 0.346], p <0.001. The mean titers of anti-HBs (log10mIU/m) were on the decrease in turn in groups of HBIG= 0 IU, HBIG= 25 IU and HBIG= 50 IU, p <0.001.Conclusions: HBIG has a negative impact on both the rate of effective immune response and response level of anti-HBs, which preliminarily indicates maternal anti-HBs inhibits infants’ immune response to HepB Vac.

Influence of maternal antibody against hepatitis B surface antigen on active immune response to hepatitis B vaccine in infants

Vaccine ◽  
2008 ◽  
Vol 26 (48) ◽  
pp. 6064-6067 ◽  
Author(s):  
Yali Hu ◽  
Qiaozhen Wu ◽  
Biyun Xu ◽  
Zhenxian Zhou ◽  
Zhiqun Wang ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Hepatitis B Vaccine ◽  
Maternal Antibody

scholarly journals Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles

2008 ◽  
Vol 69 (2) ◽  
pp. 405-416 ◽  
Author(s):  
Olga Borges ◽  
Anabela Cordeiro-da-Silva ◽  
Joana Tavares ◽  
Nuno Santarém ◽  
Adriano de Sousa ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Chitosan Nanoparticles ◽  
Nasal Delivery ◽  
Cpg Odn

scholarly journals PACKAGING OF HEPATITIS B SURFACE ANTIGEN VACCINE AND MORINGA OLEIFERA EXTRACT INTO CHITOSAN NANOPARTICLES

2019 ◽  
Vol 12 (1) ◽  
pp. 346
Author(s):  
Diky Mudhakir ◽  
Adik Ahmadi ◽  
Muhamad Insanu ◽  
Neny Nuraini
Keyword(s):  
Immune Response ◽  
Particle Size ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Moringa Oleifera ◽  
Hepatitis B Surface Antigen ◽  
Polyacrylamide Gel Electrophoresis ◽  
Sodium Dodecyl ◽  
Chitosan Nanoparticles ◽  
Entrapment Efficiency

Objective: Oftentimes, the recombinant antigen for the use of vaccines is less immunogenic than live attenuated or inactive vaccines. Hence, a potent adjuvant is needed to enhance the immune response. Moreover, the role of vector design is also important to facilitate the improvement of the immune response. The aim of this research was to develop hepatitis B surface antigen (HBsAg)-loaded nanoparticles and Moringa oleifera aqueous leaf extracts as an adjuvant using chitosan polymer. Methods: Chitosan nanoparticles were prepared by the ionic gelation method using sodium tripolyphosphate as the cross-linking agent. A system was composed of chitosan core in which HBsAg and M. oleifera extracts were incorporated. The concentration of HBsAg used in this combination was 10 μg/ml, and the concentrations of extracts were 10, 50, and 100 μg/ml, respectively. In this study, three types of nanoparticles were produced: HBsAg-loaded nanoparticles, M. oleifera-loaded nanoparticles, and combination of HBsAg–M. oleifera-loaded nanoparticles. The nanoparticles formed were characterized by the particle size, HBsAg entrapment efficiency using sodium dodecyl sulfate polyacrylamide gel electrophoresis, and the entrapment efficiency of extracts using the total flavonoid method. Results: The results showed that the particle size was between 111 and 245 nm. The entrapment efficiency of HBsAg in the separate formula was 79%, while that in the combined formula was approximately 96–98%. Furthermore, the entrapment efficiency of the extracts in the separate formula was around 64–91%, while that in the combined formula was 55–82.5%. Particularly, HBsAg–M. oleifera-loaded chitosan nanoparticles with the extract concentrations of 50 μg/ml showed the highest entrapment efficiencies of HBsAg and M. oleifera extracts of approximately 98 and 82.5%, respectively. Conclusion: Collectively, the system has been successfully developed, so it is then plausible to determine the function of the devices to enhance the immune response in the future.

Hepatitis B Vaccine in Healthy Hospital Employees

1986 ◽  
Vol 7 (7) ◽  
pp. 365-369 ◽  
Author(s):  
S.A Klotz ◽  
R. Normand ◽  
R. Silberman
Keyword(s):  
Hepatitis B ◽  
Surface Antigen ◽  
Response Rate ◽  
Hepatitis B Surface Antigen ◽  
Hepatitis B Vaccine ◽  
Protective Level ◽  
Entire Series ◽  
Hospital Employees ◽  
Lower Response Rate ◽  
Low Rate

AbstractA low rate of seroconversion to hepatitis B vaccine is reported. This occurred in healthy hospital employees from two separate institutions. A total of 236 individuals were evaluated in this study and only 53% or 124 persons developed protective levels of antibody to hepatitis B surface antigen following a complete vaccine series. In one hospital, 30% of the vaccine recipients developed antibody but not to a protective level. Employees who received the entire series in the arm or in the arm and buttock (mixed) had a significantly greater number of responders than employees who received the entire series in the buttock (P<.05). Recipients aged 50 to 59 years had a significantly lower response rate to the vaccine (P<.05). There was no correlation with the vaccinee's sex or the timing of the second injection. Vaccine was noted to have frozen in one hospital and accounted for some loss of antigenicity. This failure to respond to the vaccine has necessitated the use of booster injections of vaccine and continued antibody monitoring.

Sign in / Sign up

Export Citation Format

Share Document